Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mngmt Corp holds 238,000 shares or 0.13% of its portfolio. Montecito Retail Bank And Trust holds 0.38% or 20,511 shs. 18,771 were accumulated by Cubist Systematic Strategies. Sentinel Tru Lba owns 43,180 shares for 0.58% of their portfolio. On average, equities analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year. 6,713 were accumulated by Peddock Capital Advisors Lc. Marshwinds Advisory reported 44,088 shs or 1.25% of all its holdings. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. "Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases", said Bristol-Myers Squibb Chairman and CEO Giovanni Caforio in the statement. Bristol-Myers Squibb's dividend payout ratio is presently 53.16%.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide.
Cadinha & Co Llc decreased its stake in Bristol (BMY) by 90.91% based on its latest 2018Q3 regulatory filing with the SEC. The offer stayed at about the same level throughout the negotiations even though Celgene's share price dropped from around $80 in September to around $66 the day before the announcement, one of the sources said. Wealth Architects LLC lifted its stake in Bristol-Myers Squibb by 14.0% in the third quarter. The company has a market cap of $84.84 billion, a P/E ratio of 17.42, a price-to-earnings-growth ratio of 1.45 and a beta of 0.97. The stock increased 2.04% or $1.04 during the last trading session, reaching $51.98. About 8.44 million shares traded. The current EPS for the company has recorded at $2.67.
Many value shareholders look for stocks with a high percentage of insider ownership, under the theory that when administration is shareholders, they will act in its own self-interest, and create shareholder value in the long-term.
On February, 4 Bristol-Myers Squibb Company (NYSE:BMY)'s earnings report is anticipated by WallStreet, RTT reports.
Who wins in the cancer market in the years to come will depend on their pipeline of experimental medicines, not aging blockbusters. Bristol-Myers Squibb and Celgene expect to complete the transaction in the third quarter of 2019. The Massachusetts-based Adage Prns Grp Inc Limited Liability Company has invested 0.24% in Bristol-Myers Squibb Company (NYSE:BMY). - The Motley Fool" and the last "BMS Is A Buy On The Dip - Seeking Alpha" with publication date: "October 30, 2018. The positive are 40%. Bristol-Myers Squibb had 13 analyst reports since July 23, 2018 according to SRatingsIntel. On Tuesday, November 6 the stock rating was maintained by Morgan Stanley with "Equal-Weight".
Several equities analysts recently issued reports on BMY shares. On Monday, October 22 Citigroup downgraded Bristol-Myers Squibb Company (NYSE:BMY) to "Neutral" rating. Inc.'s holdings in Bristol-Myers Squibb were worth $1,379,000 at the end of the most recent reporting period. BMO Capital Markets lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a "market perform" rating in a report on Friday, November 16th. On Wednesday, August 8 the company was upgraded by Atlantic Securities.